GR3005238T3 - - Google Patents

Info

Publication number
GR3005238T3
GR3005238T3 GR920401572T GR920401572T GR3005238T3 GR 3005238 T3 GR3005238 T3 GR 3005238T3 GR 920401572 T GR920401572 T GR 920401572T GR 920401572 T GR920401572 T GR 920401572T GR 3005238 T3 GR3005238 T3 GR 3005238T3
Authority
GR
Greece
Application number
GR920401572T
Other languages
Greek (el)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US89796286A priority Critical
Application filed filed Critical
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25408720&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GR3005238(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of GR3005238T3 publication Critical patent/GR3005238T3/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/191Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/217IFN-gamma
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/27Growth hormone [GH] (Somatotropin)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/06Sprayers or atomisers specially adapted for therapeutic purposes of the injector type
GR920401572T 1986-08-19 1992-07-21 GR3005238T3 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US89796286A true 1986-08-19 1986-08-19

Publications (1)

Publication Number Publication Date
GR3005238T3 true GR3005238T3 (en) 1993-05-24

Family

ID=25408720

Family Applications (1)

Application Number Title Priority Date Filing Date
GR920401572T GR3005238T3 (en) 1986-08-19 1992-07-21

Country Status (8)

Country Link
US (3) US6099517A (en)
EP (1) EP0257956B2 (en)
JP (1) JP2573959B2 (en)
AT (1) AT76311T (en)
CA (1) CA1292182C (en)
DE (1) DE3779221D1 (en)
ES (1) ES2032831T5 (en)
GR (1) GR3005238T3 (en)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3779221D1 (en) * 1986-08-19 1992-06-25 Genentech Inc Device and dispersion for the intrapulmonal entering of polypeptide growth substances and cytokins.
US5037644A (en) * 1986-10-27 1991-08-06 Cetus Corporation Pharmaceutical compositions of recombinant interleukin-2 and formulation processes
US4944941A (en) * 1987-08-07 1990-07-31 Genentech, Inc. Methods and compositions for the treatment of lung conditions
JP2739733B2 (en) * 1988-08-09 1998-04-15 オムロン株式会社 Inhaler
EP0377174A3 (en) * 1988-12-22 1990-11-22 Büsselmann, Manfred Method and apparatus for spraying and atomising liquids
US5198212A (en) * 1988-10-31 1993-03-30 University Of Lousville Research Foundation Incorporated Method and compositions for treatment of trauma-associated sepsis with gamma interferon
US4994439A (en) * 1989-01-19 1991-02-19 California Biotechnology Inc. Transmembrane formulations for drug administration
US5011678A (en) * 1989-02-01 1991-04-30 California Biotechnology Inc. Composition and method for administration of pharmaceutically active substances
JPH05963A (en) * 1990-04-13 1993-01-08 Toray Ind Inc Polypeptide composition
DK0462305T3 (en) * 1990-06-21 1995-04-24 Huland Edith Use of cytokine-containing aerosols as well as cytokine-containing aerosols per se
US5780012A (en) * 1990-06-21 1998-07-14 Huland; Edith Method for reducing lung afflictions by inhalation of cytokine solutions
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
DE4117078A1 (en) * 1991-05-25 1992-11-26 Boehringer Ingelheim Kg Method for producing therapeutically applicable aerosols
US6673335B1 (en) 1992-07-08 2004-01-06 Nektar Therapeutics Compositions and methods for the pulmonary delivery of aerosolized medicaments
US7448375B2 (en) * 1993-01-29 2008-11-11 Aradigm Corporation Method of treating diabetes mellitus in a patient
US6024090A (en) * 1993-01-29 2000-02-15 Aradigm Corporation Method of treating a diabetic patient by aerosolized administration of insulin lispro
US5354934A (en) 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
IL109350A (en) * 1993-05-12 2001-01-28 Genentech Inc Stable liquid compositions of gamma interferon
US5497763A (en) * 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
US5512269A (en) * 1993-06-09 1996-04-30 Burroughs Wellcome, Co. Method of treating retained pulmonary secretions
EP0748213B1 (en) 1994-03-07 2004-04-14 Nektar Therapeutics Methods and compositions for pulmonary delivery of insulin
US20030113273A1 (en) * 1996-06-17 2003-06-19 Patton John S. Methods and compositions for pulmonary delivery of insulin
US5522385A (en) * 1994-09-27 1996-06-04 Aradigm Corporation Dynamic particle size control for aerosolized drug delivery
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US6428771B1 (en) * 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
US5972331A (en) * 1995-12-22 1999-10-26 Schering Corporation Crystalline interferon alpha for pulmonary delivery and method for producing the same
US6652837B1 (en) 1996-05-24 2003-11-25 Massachusetts Institute Of Technology Preparation of novel particles for inhalation
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
EP2042597B1 (en) 2000-06-23 2014-05-07 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
EP2168980A1 (en) 2000-06-23 2010-03-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogensis
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
JP4532733B2 (en) 1998-03-17 2010-08-25 ジェネンテック, インコーポレイテッド Polypeptides homologous to VEGF and BMP1
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
SE9803770D0 (en) * 1998-11-05 1998-11-05 Astra Ab Dry powder pharmaceutical formulation
DE19851380A1 (en) * 1998-11-07 2000-05-11 Messer Griesheim Gmbh Perfuming oxygen
MXPA01013236A (en) 1999-06-28 2002-06-21 Genentech Inc Methods for making apo-2 ligand using divalent metal ions.
DK2280021T3 (en) * 1999-06-29 2016-05-02 Mannkind Corp Pharmaceutical formulations comprising insulin complexed to a diketopiperazine
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
US6749835B1 (en) 1999-08-25 2004-06-15 Advanced Inhalation Research, Inc. Formulation for spray-drying large porous particles
JP3852256B2 (en) 1999-11-10 2006-11-29 富士ゼロックス株式会社 Inkjet recording device
JP2001187459A (en) 1999-12-28 2001-07-10 Fuji Xerox Co Ltd Ink jet recorder
MXPA02006518A (en) * 1999-12-30 2004-07-30 Intermune Inc ggr;IFN LIQUIDDROPLET AEROSOL AND METHOD.
EP1246609B1 (en) * 2000-01-14 2010-03-31 Brown University Research Foundation Process for making micronized freeze-dried particles
JP2003524646A (en) * 2000-01-25 2003-08-19 エアロファーム テクノロジー インコーポレイテッド Pharmaceutical aerosol formulation
US6585957B1 (en) 2000-01-25 2003-07-01 Aeropharm Technology Incorporated Medicinal aerosol formulation
CA2382133C (en) 2000-05-10 2010-11-23 Alliance Pharmaceutical Corporation Phospholipid-based powders for drug delivery
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
MXPA03001092A (en) * 2000-08-07 2003-09-25 Nektar Therapeutics Al Corp Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation.
JP4931282B2 (en) * 2000-10-02 2012-05-16 日本ケミカルリサーチ株式会社 Bioactive peptide-containing powder
AU1788002A (en) * 2000-11-15 2002-05-27 Scimed Life Systems Inc Device and method for treating female urinary incontinence
AU2002230993B2 (en) 2000-12-29 2006-02-02 Alkermes, Inc. Particles for inhalation having sustained release properties
WO2003029462A1 (en) * 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
CA2464690A1 (en) * 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of apolipoprotein d
JP2005508162A (en) 2001-10-02 2005-03-31 ジェネンテック・インコーポレーテッドGenentech,Inc. Apo-2 ligand variants and methods of use
AT482716T (en) 2001-11-13 2010-10-15 Genentech Inc Compositions based on apo2 ligand / trail and its use
SI1458360T1 (en) 2001-12-19 2011-08-31 Novartis Ag Pulmonary delivery of aminoglycosides
WO2003055730A1 (en) 2001-12-27 2003-07-10 Nsk Ltd. Vehicle tilt type steering device
US20040063912A1 (en) * 2002-03-15 2004-04-01 The Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics
ES2300568T3 (en) 2002-03-20 2008-06-16 Mannkind Corporation Inhalation apparatus
US20040009231A1 (en) * 2002-03-20 2004-01-15 Advanced Inhalation Research, Inc. hGH (human growth hormone) formulations for pulmonary administration
US7008644B2 (en) * 2002-03-20 2006-03-07 Advanced Inhalation Research, Inc. Method and apparatus for producing dry particles
US20050163725A1 (en) * 2002-03-20 2005-07-28 Blizzard Charles D. Method for administration of growth hormone via pulmonary delivery
EP2305710A3 (en) 2002-06-03 2013-05-29 Genentech, Inc. Synthetic antibody phage libraries
EP1556076A4 (en) 2002-06-24 2009-07-08 Genentech Inc Apo-2 ligand/trail variants and uses thereof
CA2489402A1 (en) * 2002-07-08 2004-01-15 Pliva-Istrazivacki Institut D.O.O. New compounds, compositions and methods for treatment of inflammatory diseases and conditions
JP4530851B2 (en) * 2002-07-08 2010-08-25 グラクソスミスクライン・イストラジヴァッキ・センタル・ザグレブ・ドルズバ・ゼー・オメイェノ・オドゴヴォルノスティオGlaxosmithkline Istrazivacki Centar Zagreb D.O.O. Novel compounds and compositions as carriers for steroid / nonsteroidal anti-inflammatory active molecules, anti-neoplastic active molecules and antiviral active molecules
SI2891666T1 (en) 2002-10-16 2017-11-30 Purdue Pharma L.P. Antibodies that bind cell-associated CA 125/O722P and methods of use thereof
HRP20030324A2 (en) 2003-04-24 2005-02-28 PLIVA-ISTRAŽIVAČKI INSTITUT d.o.o. Compounds of antiinflammatory effect
US7338171B2 (en) * 2003-10-27 2008-03-04 Jen-Chuen Hsieh Method and apparatus for visual drive control
WO2005067964A1 (en) * 2004-01-12 2005-07-28 Mannkind Corporation A method of reducing serum proinsulin levels in type 2 diabetics
ES2398318T3 (en) * 2004-03-12 2013-03-15 Biodel, Inc. Fast-acting drug delivery compositions
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
US7709639B2 (en) 2004-08-20 2010-05-04 Mannkind Corporation Catalysis of diketopiperazine synthesis
KR101644250B1 (en) 2004-08-23 2016-07-29 맨카인드 코포레이션 Diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug delivery
WO2006046123A2 (en) 2004-10-27 2006-05-04 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. Conjugates with anti-inflammatory activity
WO2006055950A1 (en) * 2004-11-18 2006-05-26 Nektar Therapeutics Pharmaceutical dry powder formulation on the basis particles comprising multiple active agents
AR066386A1 (en) * 2004-12-17 2009-08-19 Glenmark Pharmaceuticals Sa Condensed heterocyclic compounds, methods and intermediates for their preparation, a pharmaceutical composition comprising them and their use in treating diseases mediated by inhibition of PDE-4
UA88795C2 (en) * 2004-12-17 2009-11-25 Гленмарк Фармасьютікалс С.А. Heterocyclic compounds useful for the treatment of inflammatory and allergic disorders
JP5465878B2 (en) 2005-09-14 2014-04-09 マンカインド コーポレイション Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
WO2007041481A1 (en) * 2005-09-29 2007-04-12 Biodel, Inc. Rapid acting and prolonged acting insulin preparations
US8084420B2 (en) * 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
WO2007121256A2 (en) * 2006-04-12 2007-10-25 Biodel, Inc. Rapid acting and long acting insulin combination formulations
EP1986679B1 (en) 2006-02-22 2017-10-25 MannKind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
US7713929B2 (en) 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
GB0617417D0 (en) * 2006-09-05 2006-10-18 Concept 2 Manufacture Design L A nebuliser valve
WO2008124522A2 (en) * 2007-04-04 2008-10-16 Biodel, Inc. Amylin formulations
US20090175840A1 (en) * 2008-01-04 2009-07-09 Biodel, Inc. Insulin formulations for insulin release as a function of tissue glucose levels
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
US8499757B2 (en) 2008-06-13 2013-08-06 Mannkind Corporation Dry powder inhaler and system for drug delivery
DK2300083T3 (en) 2008-06-20 2013-07-22 Mannkind Corp Interactive device and procedure for real-time profiling inhalation tests
TWI494123B (en) 2008-08-11 2015-08-01 Mannkind Corp Use of ultrarapid acting insulin
CN102149728B (en) 2008-09-10 2014-10-15 霍夫曼-拉罗奇有限公司 Methods for inhibiting ocular angiogenesis
CN102317314A (en) 2008-10-10 2012-01-11 阿纳福公司 Polypeptides that bind TRAIL-RI and TRAIL-R2
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
US8538707B2 (en) 2009-03-11 2013-09-17 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
EP2260857A1 (en) 2009-06-11 2010-12-15 Alfact Innovation Novel applications of HIP/PAP or derivatives thereof
WO2010144789A2 (en) 2009-06-12 2010-12-16 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
EP2496295A1 (en) 2009-11-03 2012-09-12 MannKind Corporation An apparatus and method for simulating inhalation efforts
CN102770764B (en) 2009-12-07 2016-04-20 皮里斯股份公司 Given target is had to the mutain of people's ALPHA-2u (Lcn2, hNGAL) of avidity
CN102985125A (en) 2010-06-21 2013-03-20 曼金德公司 Dry powder drug delivery system and methods
BR112013023120A2 (en) 2011-03-10 2017-09-19 Genentech Inc method of treating a dysfunction associated with altered vascular barrier function in a subject, method of reducing or inhibiting vascular barrier function in a subject in need thereof and method of treating a dysfunction requiring formation of new blood vessels in a subject
CN105667994B (en) 2011-04-01 2018-04-06 曼金德公司 Blister package for pharmaceutical kit
MX2013012716A (en) 2011-05-03 2014-03-21 Genentech Inc Vascular disruption agents and uses thereof.
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
WO2013063160A1 (en) 2011-10-24 2013-05-02 Mannkind Corporation Methods and compositions for treating pain
SG10201605800UA (en) 2012-07-12 2016-09-29 Mannkind Corp Dry powder drug delivery system and methods
EP2687225A1 (en) 2012-07-19 2014-01-22 Alfact Innovation HIP/PAP protein and derivatives thereof for use in treating cancer
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
CA2891557A1 (en) 2013-03-26 2014-05-22 Pieris Ag Novel specific-binding polypeptides and uses thereof
EP3587404A1 (en) 2013-03-15 2020-01-01 MannKind Corporation Microcrystalline diketopiperazine compositions, methods for preparation and use thereof
MX2016000739A (en) 2013-07-18 2017-04-06 Mannkind Corp Heat-stable dry powder pharmaceutical compositions and methods.
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
CA2888068A1 (en) 2014-04-15 2015-10-15 The Hospital For Sick Children Cationic antimicrobial peptides
KR20170004011A (en) 2014-05-22 2017-01-10 피어이스 파마슈티컬즈 게엠베하 Novel specific-binding polypeptides and uses thereof
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
CN107207574A (en) 2015-01-28 2017-09-26 皮里斯制药有限公司 The specific novel protein of angiogenesis
US10273275B2 (en) 2015-05-18 2019-04-30 Pieris Pharmaceuticals Gmbh Muteins of human lipocalin 2 with affinity for glypican-3 (GPC3) and methods of use thereof
WO2017091850A1 (en) 2015-11-30 2017-06-08 Pieris Australia Pty Ltd. Novel anti-angiogenic fusion polypeptides
TW201725212A (en) 2015-12-10 2017-07-16 第一三共股份有限公司 Novel proteins specific for calcitonin gene-related peptide

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4537878A (en) 1981-10-05 1985-08-27 Tni Pharmaceuticals, Inc. Process for using endogenous enkephalins and endorphins to stimulate the immune system
US4771769A (en) 1982-12-20 1988-09-20 Schering Corporation Hand held metered spray dispenser
JPS6237016B2 (en) 1983-03-09 1987-08-10 Teijin Ltd
US4481191A (en) 1983-03-30 1984-11-06 The Regents Of The University Of California Method for controlling blood pressure
US4548922A (en) 1983-06-06 1985-10-22 Beth Israel Hospital Drug administration
US4959358A (en) 1983-06-06 1990-09-25 Beth Israel Hospital Assn. Drug administration
US4746508A (en) 1983-06-06 1988-05-24 Beth Israel Hospital Assn. Drug administration
US4699136A (en) 1983-12-22 1987-10-13 Krauser Robert S Method and apparatus for treating ailments
US5082658A (en) 1984-01-16 1992-01-21 Genentech, Inc. Gamma interferon-interleukin-2 synergism
JPS60161924A (en) 1984-02-01 1985-08-23 Fujisawa Pharmaceut Co Ltd Composition for lung absorption
US4645828A (en) 1984-03-23 1987-02-24 Oncogen Platelet related growth regulator
US4590003A (en) 1984-03-23 1986-05-20 Oncogen Platelet related growth regulator
DE3470380D1 (en) * 1984-08-09 1988-05-19 Inge Brugger Nebulizer
ZA8406192B (en) 1984-08-09 1986-03-26 Merck Patent Gmbh Immunotherapeutic polypeptide agents
GB2172590A (en) * 1985-03-19 1986-09-24 Emhart Ind Mould arrangement of a glassware forming machine
JPS6248634A (en) 1985-07-23 1987-03-03 Hayashibara Biochem Lab Inc Novel amino acid composition, production thereof and pharmaceutical composition containing said amino acid composition
DE3779221D1 (en) * 1986-08-19 1992-06-25 Genentech Inc Device and dispersion for the intrapulmonal entering of polypeptide growth substances and cytokins.
US4710305A (en) 1986-12-29 1987-12-01 Conoco Inc. Processes and oxidizing agents for oxidizing sulfide ion to innocuous, soluble sulfur species
NZ241954A (en) 1991-03-15 1994-01-26 Amgen Inc Compositions of g-csf for pulmonary administration.
US5354934A (en) 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
DE10006167B4 (en) * 2000-02-11 2009-07-23 Abb Schweiz Ag breakers
DE10032433A1 (en) * 2000-07-04 2002-01-17 H A N D Gmbh Ground space monitoring procedures

Also Published As

Publication number Publication date
AT76311T (en) 1992-06-15
EP0257956B2 (en) 2000-11-22
EP0257956A3 (en) 1989-04-19
US6099517A (en) 2000-08-08
EP0257956B1 (en) 1992-05-20
ES2032831T3 (en) 1993-03-01
JP2573959B2 (en) 1997-01-22
EP0257956A2 (en) 1988-03-02
JPS6351868A (en) 1988-03-04
DE3779221D1 (en) 1992-06-25
US20020193730A1 (en) 2002-12-19
ES2032831T5 (en) 2001-02-16
CA1292182C (en) 1991-11-19
US6402733B1 (en) 2002-06-11

Similar Documents

Publication Publication Date Title
JPH039267Y2 (en)
JPS62127140U (en)
JPH0434907B2 (en)
GR3005137T3 (en)
JPS6369692U (en)
JPS6354101U (en)
GB2186565B (en)
JPH0356701B2 (en)
JPS63503123A (en)
JPH01503296A (en)
JPH052129Y2 (en)
JPH055259B2 (en)
JPH051840B2 (en)
JPS62153240U (en)
JPS644873B2 (en)
IN167074B (en)
JPH0255303B2 (en)
JPH0577210B2 (en)
IN165691B (en)
JPS6312926U (en)
JPS6374794U (en)
JPH0567228B2 (en)
JPH0577683B2 (en)
JPH0262349B2 (en)
JPH0446847B2 (en)